Lupus & antiphospholipid syndrome
Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus
Authors' conclusion
Together, these results show that anti-Sm/RNP and anti-dsDNA, in contrast to anti-SS-A/SS-B, frequently fluctuate and their levels can decrease following B cell-targeted treatments.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE): electronic health records, a longitudinal cohort, and patients treated with RTX and belimumab
- Exposure
- Dynamics of specific antinuclear antibodies (ANAs) (Anti-double-stranded DNA (anti-dsDNA), anti-Smith (anti-Sm)/RNP, anti-SS-A/SS-B) vs stable anti-VZV controls; titers after RTX and belimumab
- Outcome
- Dynamics (seroconversion and titer fluctuation) of specific ANAs and their susceptibility to B cell-targeting treatments
Methodological detailslongitudinal cohort, electronic health records
- Longitudinal cohort
- Electronic health records
Main finding
As reported in the abstract
ANA dynamics
- Anti-Sm and anti-RNP, similar to anti-dsDNA, seroconverted more frequently than anti-SS-A/SS-B
- Anti-Sm/RNP and anti-dsDNA titers, but not anti-SS-A/SS-B, fluctuated significantly vs stable anti-VZV controls
Observational data: associations, not effects.
Further findings
Titer reduction after B cell-depleting treatment
- Reductions in anti-dsDNA and anti-Sm/RNP titers comparable in magnitude
- Only anti-dsDNA titer reductions associated with clinical outcomes
Original publication
Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. Published 2 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →